BioTuesdays

Tag - Matthew Kaplan

Cogent Biosciences Logo

Ladenburg starts Cogent Biosciences at buy; PT $4

Ladenburg Thalmann launched coverage of Cogent Biosciences (NASDAQ:COGT) with a “buy” rating and $4 price target. The stock closed at $2.89 on Oct. 13. Cogent has a late-stage clinical asset, CGT9486, in development for...

Eyenovia Logo

Ladenburg cuts Eyenovia PT to $19 from $30

Ladenburg Thalmann lowered its price target for Eyenovia (NASDAQ:EYEN) to $19 from $30, but reiterated its “buy” rating, reflecting dilution associated with a recent financing and anticipated additional dilution...

Allena Pharmaceuticals Logo

Ladenburg lowers Allena Pharma PT to $13 from $23

Ladenburg Thalmann lowered its price target for Allena Pharmaceuticals (NASDAQ:ALNA) to $13 from $23 largely driven by an increase in the number of shares outstanding, assuming an equity financing. The stock closed at...

Avadel Logo

Ladenburg ups PT for Avadel Pharma to $14 from $8

Ladenburg Thalmann raised its price target for Avadel Pharmaceuticals (NASDAQ:AVDL) to $14 from $8 after the company completed enrollment in its REST-ON Phase 3 study, with a pivotal data readout expected in the second...

ArTara Therapeutics

Ladenburg starts ArTara Therapeutics at buy; PT $45

Ladenburg Thalmann initiated coverage of ArTara Therapeutics (NASDAQ:TARA) with a “buy” rating and $45 price target. The stock closed at $28.34 on Jan. 21. ArTara has two late-stage clinical assets in development for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.